alexa
ISSN: 2165-7831
Journal of Blood & Lymph
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Hodgkin's Disease: Past to Present

Priyanka Pathak*
Physician, Kimmel Cancer Center, Department of Medical Oncology, Thomas Jefferson University, PA, USA
Corresponding Author : Priyanka Pathak, MD, MPH
Physician, Kimmel Cancer Center
Department of Medical Oncology
Thomas Jefferson University
111 S. 11th St, Philadelphia, PA 19107, USA
Tel: 281-536-9472
E-mail: Priyanka.pathak@jefferson.edu
Received March 28, 2015; Accepted March 30, 2015; Published April 10, 2015
Citation: Pathak P (2015) Hodgkin’s Disease: Past to Present. J Blood Lymph 5:e118. doi: 10.4172/2165-7831.1000e118
Copyright: © 2015 Pathak P, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Blood & Lymph

Editorial
Hodgkin’s disease (HD) is an uncommon malignancy accounting for an incidence of 0.6% of all cancers. In 2015, an estimated 9,050 people will be diagnosed with HD in the United States and 1,150 people will die from the disease [1]. From 2007 to 2011, the incidence rates for HD have been stable but death rates have been steadily decreasing by 2.2% per year for men and 2.7% for women per year for women. The latter have been attributed to better therapeutic interventions.
Once considered, the “inexorably fatal condition”, HD had long been a subject of controversy with respect to its nature, etiology and therapy. Initially thought to be an infectious disease due to its association with tuberculosis, definitive evidence of its neoplastic nature came in the 1960’s when cytogenetic studies confirmed its clonal derivation and aneuploidy.
The contiguous nature of its spread via lymphatic channels which was demonstrated when laparotomy was used as a staging tool at the Stanford University Medical Center for the first time in 1969, changed prevailing ideas of its treatment from essentially symptomatic to curative [2]. Treatment of HD has been fraught with controversy, ranging from surgical approaches which are no longer used, radiotherapy (extended field radiation versus involved field radiation) and chemotherapy (single versus multidrug regimens).
This disease has served as a model for the development of combined modality therapy with a multidisciplinary approach involving radiation oncologists, medical oncologists and radiologists. It has also served as the basis for interim PET/CT scans in the prognostication of other lymphomas and its treatment started the era of multi-agent chemotherapy for other hematologic malignancies.
HD has also been instrumental in the designing of long term studies which enables the assessment of the long-term effects of a treatment and helps us seek a balance between treatment effectiveness and the avoidance of long term gonadal, cardiac and secondary neoplastic complications.
Currently, the standard of care for previously untreated HD in the United States is combined modality therapy for Stage I and Stage II disease and combination chemotherapy (ABVD, Stanford V and BEACOPP) for advanced stages [3]. The 5 year survival rates for HD range from 90.8% for localized disease to 76.2% for distant disease [4]. Thus, we have come a long way from a potentially fatal disease to an imminently curable one.
In this issue, Salvatore et al. present a case of a 44 year old woman who presented with a bulky Stage II Hodgkin’s lymphoma with mediastinal syndrome. The patient had been aware of the tumor for about three years prior to her admission. This case report showcases a few important details- namely the natural history of Hodgkin’s disease which is rare with current medical advances, the effectiveness of current treatments and the social stigma of cancer which prevented her from seeking medical treatment leading to the fatal outcome.
References

 

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • 7th World Hematologists Congress May 08-09, 2017 Barcelona, Spain
    May 08-09, 2017 Barcelona, Spain
  • 8th International Conference on Blood Cancer & Treatment June 26-27, 2017 London, UK
    June 26-27, 2017 London, UK
  • International Conference on Hematology and Oncology June 29-July 01, 2017 Bangkok, Thailand
    June 29-July 01, 2017 Bangkok, Thailand
  • 9th International Conference on Hematology November 02-03, 2017 Las Vegas, USA
    November 02-03, 2017 Las Vegas, USA
  • 11th International Conference on Leukemia and Hematologic Oncology December 04-05, 2017 Madrid, Spain
    December 04-05, 2017 Madrid, Spain

Article Usage

  • Total views: 11346
  • [From(publication date):
    April-2015 - Dec 10, 2016]
  • Breakdown by view type
  • HTML page views : 7610
  • PDF downloads :3736
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsonline.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsonline.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsonline.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsonline.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsonline.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsonline.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsonline.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsonline.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsonline.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsonline.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsonline.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsonline.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsonline.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsonline.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsonline.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsonline.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version